Amiodarone-metoprolol co-administration enhances heart rate variability and suppresses inflammatory cytokines in tachyarrhythmia patients.

OBJECTIVE

To elucidate the efficacy of amiodarone (AMD)-metoprolol (MET) co-administration in tachyarrhythmia patients, and to assess its impact on heart rate (HR) variability (HRV) and serum inflammatory cytokines (SICs).

METHODS

This study included 188 tachyarrhythmia patients who were treated at the Qinghai Provincial Fourth People's Hospital, including 88 patients treated with AMD (control group) and 100 patients treated with AMD+MET (research group). We compared the following clinical data between groups: curative effects, frequency and duration of arrhythmia episodes, vital signs, cardiac function (left ventricular [LV] ejection fraction [LVEF], LV systolic diameter [LVSD], LV end-diastolic diameter [LVEDD]), HRV, SICs, oxidative stress (superoxide dismutase [SOD], malondialdehyde [MDA]), and side effects. In addition, we explored factors influencing patients' curative effects.

RESULTS

A higher total effective rate was observed in the research group compared with the control group (91.00% vs. 79.55%, P=0.025). In addition, the research group experienced fewer arrhythmia episodes with shorter durations (P<0.001), and a lower incidence of total adverse events (9.00% vs. 23.86%, P=0.006). A more pronounced drop in post-treatment vital signs, LVSD, LVEDD, various SICs, and MDA (all P<0.001), as well as a rise in LVEF (P<0.001), HRV indices (P<0.001), and SOD (P=0.002), were determined in the research group. LVEF, SDNN, and LF at baseline, as well as therapeutic method, independently influenced patients' efficacy.

CONCLUSION

AMD in combination with MET yields superior efficacy in tachyarrhythmia patients, significantly improving HRV and suppressing SICs.